Litcius/Paper detail

Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries

Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Thein, Erik Hillo Lørup, Mia‐Louise Nielsen, Lea K. Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, René Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen, Lene Dreyer

2022Seminars in Arthritis and Rheumatism87 citationsDOI

Topics & Concepts

MedicinePsoriatic arthritisPsoriasisRheumatoid arthritisCohortDermatologyInternal medicineArthritisRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and TreatmentsPsoriasis: Treatment and Pathogenesis
Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries | Litcius